Qualitative Research on IgPro20 Pre‑Filled Syringe Use Among US Patients with Primary Immunodeficiencies
Patient Preference and Adherence · 2026-10 · Volume 20 · 1-19
DOI: 10.2147/ppa.s635243 ↗Kurz gefasst
Qualitative Studie in der Zeitschrift Patient Preference and Adherence, 2026-10. Verfasst von Batyrkhan Kuatov und 6 weiteren Autor:innen. Beteiligte Einrichtung: HEOR, Global Market Access, CSL Behring, Bern, Switzerland. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Purpose
Primary immunodeficiency (PID) patients can receive subcutaneous immunoglobulin (SCIG) therapy using vials or pre-filled syringes (PFS). This research explored patient experience in the United States (US) with both presentation forms related to adherence, satisfaction, convenience, and impacts to quality-of-life. Patients and Methods: A cross-sectional, qualitative interview study of 24 US PID patients currently administering IgPro20 PFS and who have prior experience in using vials.
Results
Patient's mean age was 54 years (median = 51, range 23-79), 17% were male and 83% were female, and mean time since diagnosis was 16 years (median = 12, range 3-47). Most patients (83%) reported being more satisfied with IgPro20 PFS than vials and found them more convenient (75%). Reasons included readiness for use, shorter preparation time, and no residual product. More patients reported never missing or skipping a dose with IgPro20 PFS (67%) compared with vials (29%), citing reasons such as ease of preparation and IgPro20 PFS being more travel-friendly. Moreover, 50% of patients reported positive emotional impact of changing from vials to IgPro20 PFS, related to being less anxious. As expected, there was neutrality for overall health, and daily, work-related, and social activities.
Conclusion
Participants experienced in both SCIG presentation forms were more satisfied, reported improved convenience, and were more adherent with IgPro20 PFS compared with vials. The positive benefits expressed included reduced residual product and emotional impacts driven by greater assurance of taking their full dose. Further research is required to more fully illustrate the perceptions of patients and how this potentially impacts their quality-of-life.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- HEOR, Global Market Access, CSL Behring, Bern, Switzerland.
- Kielo Research, York, UK.
- Kielo Research, Zug, Switzerland.
- Anita Burrell Consulting LLC, Flemington, NJ, USA.
- Medical Affairs and HTA Statistics, CSL Behring, Waltham, MA, USA.
- Patient Centered Science, CSL Behring, Waltham, MA, USA.
ORCID-Profile: Gemma Al-Jassar, Anita Burrell
Zitieren
APA
Kuatov, B., Al-Jassar, G., Rudell, K., Tervonen, T., Burrell, A., Weng, S., & Braverman, J. (2026). Qualitative Research on IgPro20 Pre‑Filled Syringe Use Among US Patients with Primary Immunodeficiencies. Patient Preference and Adherence, Volume 20, 1-19. https://doi.org/10.2147/ppa.s635243
Vancouver
Kuatov B, Al-Jassar G, Rudell K, Tervonen T, Burrell A, Weng S, et al. Qualitative Research on IgPro20 Pre‑Filled Syringe Use Among US Patients with Primary Immunodeficiencies. Patient Preference and Adherence. 2026;Volume 20:1-19. doi:10.2147/ppa.s635243
BibTeX
@article{Kuatov2026,
author = {Kuatov, Batyrkhan and Al-Jassar, Gemma and Rudell, Katja and Tervonen, Tommi and Burrell, Anita and Weng, Shicheng and Braverman, Julia},
title = {Qualitative Research on IgPro20 Pre‑Filled Syringe Use Among US Patients with Primary Immunodeficiencies},
journal = {Patient Preference and Adherence},
year = {2026},
volume = {Volume 20},
pages = {1--19},
doi = {10.2147/ppa.s635243}
}
EUVIMED